SAREPTA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $13.98, a 80.68% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $46.93, a 30.28% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $67.31, a 5.12% decline from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $70.94, a 45.31% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $48.82, a 1.37% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $46.93 10-K · filed 2026-03-02 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $46.93 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $13.98 10-Q · filed 2026-08-05 | $46.93 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $48.49 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | $67.31 10-K · filed 2026-03-02 | ||||
| 2024-09-30 | $55.16 10-Q · filed 2025-11-06 | $67.39 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $72.37 10-Q · filed 2025-08-06 | $67.63 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $67.56 10-Q · filed 2025-05-06 | ||||
| 2023-12-31 | $70.94 10-K · filed 2026-03-02 | ||||
| 2023-09-30 | $66.53 10-Q · filed 2024-11-06 | $72.23 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $66.82 10-Q · filed 2024-08-07 | $72.50 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $72.80 10-Q · filed 2024-05-01 | ||||
| 2022-12-31 | $48.82 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $59.84 10-Q · filed 2023-11-01 | $47.54 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | $43.40 10-Q · filed 2023-08-02 | $46.49 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | $46.99 10-Q · filed 2023-05-02 | ||||
| 2021-12-31 | $48.16 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $42.62 10-Q · filed 2022-11-02 | $48.50 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $39.79 10-Q · filed 2022-08-02 | $48.87 10-Q · filed 2022-08-02 | |||
| 2020-12-31 | $61.38 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $61.38 10-K · filed 2022-03-01 | $70.93 10-K · filed 2020-02-26 | |||
| 2018-12-31 | $70.93 10-K · filed 2022-03-01 | $44.66 10-K · filed 2019-02-28 | |||
| 2017-12-31 | $14.78 10-K · filed 2020-02-26 | ||||
| 2016-12-31 | $12.46 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $14.98 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $24.05 10-Q · filed 2015-11-05 | $14.67 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $15.69 10-Q · filed 2015-08-06 | $11.34 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $10.35 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $18.59 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $16.19 10-Q · filed 2015-11-05 | $19.24 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | $23.68 10-Q · filed 2015-08-06 | $19.80 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | $19.41 10-Q · filed 2015-05-07 | ||||
| 2013-12-31 | $22.86 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $26.92 10-Q · filed 2013-11-12 | $23.25 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $23.20 10-Q · filed 2013-08-08 | $22.50 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $18.08 10-Q · filed 2013-05-09 | ||||
| 2012-12-31 | $9.54 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $7.09 10-Q · filed 2013-11-12 | $6.52 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | $3.53 10-Q · filed 2013-08-08 | $4.56 10-Q · filed 2013-08-08 | |||
| 2012-03-31 | $5.46 10-Q · filed 2013-05-09 | ||||
| 2011-12-31 | $6.12 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |